This experiment reveals the mechanism of action by which genetic and pharmacological inhibition of METTL3 attenuates TAB3 m6A modification through an IGF2BP2-dependent mechanism, thereby reducing renal injury and inflammation, suggesting the METTL3/TAB3 axis as a potential target for the treatment of AKI. The gene discussed is IGF2BP2; the disease is acute kidney injury.